Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.

Steven Richard FeldmanJingchuan ZhangDiane J MartinezLorena Lopez-GonzalezElizabeth Hoit MarchlewiczGeorge ShradyAlan M MendelsohnYang Zhao

Published in: The Journal of dermatological treatment (2019)

Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs.

Keyphrases

healthcare
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
coronary artery disease
patient reported outcomes
early onset
health insurance
replacement therapy